<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93F82619-4BD0-4973-B51D-2600DB517FE8"><gtr:id>93F82619-4BD0-4973-B51D-2600DB517FE8</gtr:id><gtr:name>Tau Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93F82619-4BD0-4973-B51D-2600DB517FE8"><gtr:id>93F82619-4BD0-4973-B51D-2600DB517FE8</gtr:id><gtr:name>Tau Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AF9C8839-DC02-4BD9-A438-846BF3C602F1"><gtr:id>AF9C8839-DC02-4BD9-A438-846BF3C602F1</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Shattock</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/920CD1D8-8354-4EA2-A0FC-A8C72D06FA98"><gtr:id>920CD1D8-8354-4EA2-A0FC-A8C72D06FA98</gtr:id><gtr:firstName>L</gtr:firstName><gtr:surname>Mclatchie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4C6C2280-E447-4C19-9D20-757A68708B83"><gtr:id>4C6C2280-E447-4C19-9D20-757A68708B83</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0001230"><gtr:id>FA4F7888-B3C5-4460-A2D9-126217B7FA65</gtr:id><gtr:title>Role of the T-type calcium channel in cardiac myocyte hypertrophy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0001230</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>208364</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of British Columbia</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>T-type channels in neonatal cardiac hypertrophy - Snutch</gtr:description><gtr:id>32384CA0-3430-41AE-A3C0-E5183466A6FB</gtr:id><gtr:impact>A paper is in preparation but no published output as yet.</gtr:impact><gtr:outcomeId>iTKSfNrdmdU-1</gtr:outcomeId><gtr:partnerContribution>We have a research fellow funded by a Canadian Fellowship working in my lab in London. This fellow has added to our understanding of the role of T-type channels in cardiac hypertrophy and specifically the ability of PUFA to block both these channels and the ensuing hypertrophy.</gtr:partnerContribution><gtr:piContribution>We are hosting a research fellow from the University of British Columbia in our lab in London. This fellow is paid by a Canadian fellowship but is working in London on a collaborative project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tau Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>T-channels in disease - Tau</gtr:description><gtr:id>F41911AF-A164-47F1-A3F5-AA3034C6581E</gtr:id><gtr:impact>This has been a collaboration with Tau Therapeutics. They have contributed by providing reagents and discussion as well as pooling data to try to understand T-channels in cell growth. This has helped as there are few people world-wide working in this area.; They have provided us with a novel T channel blocking agent which has proved effective in limiting cardiac hypertrophy in cell cultures. It has also lead to testing their compound in a renal model of disease - studies which are ongoing.</gtr:impact><gtr:outcomeId>95DF2FF0083-1</gtr:outcomeId><gtr:partnerContribution>They have provided us with a novel T channel blocking agent which has proved effective in limiting cardiac hypertrophy in cell cultures. It has also lead to testing their compound in a renal model of disease - studies which are ongoing.</gtr:partnerContribution><gtr:piContribution>We have on going discussions with them about the use of their compounds to treat cardiovascular disease.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hoffman La Roche promotional video</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3DD304B4-7951-4191-A46C-D8E8B82C781C</gtr:id><gtr:impact>I made a promotional video for use by Hoffman La Roche's marketing department to promote the idea of T-type Ca channels as therapeutic targets in disease. This video would have been used by them to target other healthcare professionals. Since their drug has now been withdrawn, it will no longer be used.

None that I know of.</gtr:impact><gtr:outcomeId>GA3R4m5mWdt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hoffman La Roche - marketing slide set</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2955FEA1-424A-468C-A3B1-09F42B6A7EC1</gtr:id><gtr:impact>I designed and produced a slide set explaining T-type channel physiology which Roche's sales representatives then used to explain the concept of the T channel as a therapeutic target. This was distributed to 100's of their sales team. This is no longer in use however as the drug has been withdrawn.

None that I am aware of.</gtr:impact><gtr:outcomeId>Hp2JY27QvS6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hoffman La Roche UK Advisory Board</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63D176E1-0C33-4C1D-A168-93573D706E2C</gtr:id><gtr:impact>This was entirely limited to 'industrial' engagement i.e. convincing Hoffman La Roche of the advantages of basic science and approaching clinical problems by understanding pre-clinical physiology.

None</gtr:impact><gtr:outcomeId>Ypft1HCKc1N</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hoffman La Roche GP Education</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8BED3133-9B1E-4153-A198-A648F0CFD23E</gtr:id><gtr:impact>Gave over 30 lectures around the country to GPs and other front-line health professionals on the physiology and pathophysiology of T-type Ca channels.

I was also subsequently asked to run 3 training days educating Hoffman La Roche's sales team about T-type Ca channels.</gtr:impact><gtr:outcomeId>h8DJmAXmPut</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tau Therapeutics Expert Advisory Board</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E2839EE5-9C6B-4EC3-9A5C-7D99AD91B150</gtr:id><gtr:impact>Presented work to Tau Pharmaceuticals Expert Advisory Board in the USA

Continued collaboration.</gtr:impact><gtr:outcomeId>7B239818D96</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>214119</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical PhD Fellowship</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>597A1B42-C65D-43CB-9D4E-C536EB062D0A</gtr:id><gtr:outcomeId>685237A92950</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199657</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK Research Project Grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>RP39/2014</gtr:fundingRef><gtr:id>84A275C9-3EB7-4431-AFBF-D934D28EDFC7</gtr:id><gtr:outcomeId>563a021fb9c798.07528224</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8C54A914-DF1C-4A82-9804-F60B41979CFF</gtr:id><gtr:title>A separate pool of cardiac phospholemman that does not regulate or associate with the sodium pump: multimers of phospholemman in ventricular muscle.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/098804572e5bf997c52e40d1dfd9418b"><gtr:id>098804572e5bf997c52e40d1dfd9418b</gtr:id><gtr:otherNames>Wypijewski KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14543_23_23532852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABDC22E8-11FC-4D6E-A303-FB649EB428C2</gtr:id><gtr:title>Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension.</gtr:title><gtr:parentPublicationTitle>Pharmacology research &amp; perspectives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d664a069fddc2c4e8131fe710d509e17"><gtr:id>d664a069fddc2c4e8131fe710d509e17</gtr:id><gtr:otherNames>Bodkin JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-1707</gtr:issn><gtr:outcomeId>56e1931e3fc548.44709802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79CF5B36-E0FB-450B-9A47-1560AC3D72FC</gtr:id><gtr:title>Inhibition of human mesangial cell proliferation by targeting T-type calcium channels.</gtr:title><gtr:parentPublicationTitle>Nephron. Experimental nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634aacd773479540ecf148a1bc361b34"><gtr:id>634aacd773479540ecf148a1bc361b34</gtr:id><gtr:otherNames>Mulgrew CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1660-2129</gtr:issn><gtr:outcomeId>9BE30A83B89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378FACF2-E192-4288-92EA-22B55446C963</gtr:id><gtr:title>Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e440ce56220b3161515e52e9e9f6a633"><gtr:id>e440ce56220b3161515e52e9e9f6a633</gtr:id><gtr:otherNames>Cove-Smith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_14543_23_23746655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654CBEF7-100C-4520-A36D-B5C4BEC09CD0</gtr:id><gtr:title>Regulation of the cardiac Na(+) pump by palmitoylation of its catalytic and regulatory subunits.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5beb3bd6833f19d9b46b180f3784a56e"><gtr:id>5beb3bd6833f19d9b46b180f3784a56e</gtr:id><gtr:otherNames>Howie J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_14543_23_23356265</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0001230</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>